Skip to content

Neurodegeneration Panel Consortium

Neurodegeneration Panel Consortium Overview

The Neurodegeneration Panel Consortium was formed as a collaboration to bring together leading researchers in the neuroscience community. Consortium members contributed their expertise to the design and development of a sequencing panel for neurodegenerative disease research.

The TruSeq Neurodegeneration Panel is a targeted next-generation sequencing (NGS) panel that covers 118 risk genes associated with common neurodegenerative diseases, including Alzheimer’s Disease, Parkinson's Disease, and others. 

TruSeq Neurodegeneration Panel Highlights

The content of the TruSeq Neurodegeneration Panel was carefully selected based on recent scientific findings. It features over 8.7 Mb of content, including introns, exons, untranslated regions, and promoters to support surveys of both coding and noncoding gene regions.

The panel uses tagmentation technology for rapid library prep, and is part of a convenient workflow that includes sequencing and intuitive data analysis.

Enabling Discovery of Rare Risk Variants

The TruSeq Neurodegeneration Panel aims to help researchers identify genetic variants that may shed light on neuropathological onset and progression.

Learn More

TruSeq Neurodegeneration Panel Content

Experts in neurodegenerative disease research carefully selected content for the TruSeq Neurodegeneration Panel based on recent scientific studies. The panel includes both risk-validated genes and genes thought to be associated with the following neurodegenerative diseases:

  • Alzheimer's disease
  • Parkinson's disease
  • Amyotrophic lateral sclerosis
  • Frontotemporal dementia
  • Dementia with lewy bodies
  • Dystonia
  • Early-onset dementia
Genetic Insight into Neurodegenerative Disorders

Recognizing a need for this research tool, Alan Pittman, PhD and others helped Illumina design the TruSeq Neurodegeneration Panel.

Read Interview